Treatment of respiratory infections


In a controlled, randomised, blinded multicentre field, the efficacy of Veraflox® 2.5 % oral suspension was compared to that of an authorised control product, amoxicillin/clavulanic acid suspension (Synulox®), in the treatment of upper respiratory tract infections in cats 17.
All cats considered suitable for inclusion underwent a clinical examination, and oropharyngeal swabs were taken for bacteriological analysis and detection of Feline Herpes Virus-1 (FHV-1)-DNA. Serum samples were taken to check for Feline Calici Virus (FCV), Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV) antibodies. Cats were re-examined at the end of treatment and approximately 5 days after the end of treatment, to assess response to treatment by an objective assessment of general condition and clinical signs of upper respiratory tract infection.

Rate this page

latest documents

3rd row with links